Professional
Added to YB: 2025-07-03
Pitch date: 2025-06-30
IKNA [neutral]
Ikena Oncology, Inc.
+5.93%
current return
Author Info
Clark Street Value is a special sits/event-driven investor. Sign up for the newsletter.
Company Info
Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance.
Market Cap
$69.0M
Pitch Price
$16.20
Price Target
N/A
Dividend
N/A
EV/EBITDA
0.58
P/E
-2.24
EV/Sales
N/A
Sector
Pharmaceuticals
Category
special_situation
Clark Street Value Mid Year 2025 Portfolio Review: Current Position - Ikena Oncology, Inc.
IKNA (holding update): Ikena's reverse-merger with InmageneBio (IMG-007 Ph2b asset for atopic dermatitis) trading below expected $2.05/sh cash value. Deal likely passing despite some opposition (BML 8.4% against, but 25.8% committed). Potential post-close bump when shareholder base rotates.
Read full article (1 min)